(Q33821528)

English

Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial (English)

1 reference

Europe PubMed Central

29 July 2017

phase III clinical trial

0 references

metastatic breast cancer

1 reference

based on heuristic

inferred from title

Maria Carmela Piccirillo

10

object named as

Maria Carmela Piccirillo

1 reference

Europe PubMed Central

29 July 2017

14

object named as

Gerardo Botti

1 reference

Europe PubMed Central

29 July 2017

Alessandro Morabito

2

object named as

Alessandro Morabito

1 reference

Europe PubMed Central

29 July 2017

Maurizio Di Bonito

15

object named as

Maurizio Di Bonito

1 reference

Europe PubMed Central

29 July 2017

Massimo Rinaldo

13

object named as

Massimo Rinaldo

1 reference

Europe PubMed Central

29 July 2017

12

object named as

Renato Thomas

1 reference

Europe PubMed Central

29 July 2017

Giuseppe D'Aiuto

11

object named as

Giuseppe D'Aiuto

1 reference

Europe PubMed Central

29 July 2017

Vincenzo Labonia

7

object named as

Vincenzo Labonia

1 reference

Europe PubMed Central

29 July 2017

Francesco Nuzzo

1

object named as

Francesco Nuzzo

1 reference

Europe PubMed Central

29 July 2017

Ermelinda De Maio

9

object named as

Ermelinda De Maio

1 reference

Europe PubMed Central

29 July 2017

Adriano Gravina

3

object named as

Adriano Gravina

1 reference

Europe PubMed Central

29 July 2017

6

object named as

Carmen Pacilio

1 reference

Europe PubMed Central

29 July 2017

Francesca Di Rella

4

object named as

Francesca Di Rella

1 reference

Europe PubMed Central

29 July 2017

author name string

Gabriella Landi

5

1 reference

Europe PubMed Central

29 July 2017

Emanuela Rossi

8

1 reference

Europe PubMed Central

29 July 2017

Massimo Di Maio

16

1 reference

Europe PubMed Central

29 July 2017

Ciro Gallo

17

1 reference

Europe PubMed Central

29 July 2017

Francesco Perrone

18

1 reference

Europe PubMed Central

29 July 2017

Andrea de Matteis

19

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

16 February 2011

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

11

1 reference

Europe PubMed Central

29 July 2017

75

1 reference

Europe PubMed Central

29 July 2017

https://scigraph.springernature.com/pub.10.1186/1471-2407-11-75

0 references

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050853

28 July 2018

Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050853

28 July 2018

Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050853

28 July 2018

Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Gr

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050853

28 July 2018

Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050853

28 July 2018

Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050853

28 July 2018

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050853

28 July 2018

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050853

28 July 2018

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050853

28 July 2018

Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050853

28 July 2018

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050853

28 July 2018

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050853

28 July 2018

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050853

28 July 2018

Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lung Cancer Working Party

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3050853

28 July 2018

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-75

21 January 2018

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-75

21 January 2018

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-75

21 January 2018

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-75

21 January 2018

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-75

21 January 2018

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-75

21 January 2018

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-75

21 January 2018

Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-75

21 January 2018

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-75

21 January 2018

Prospective assessment of emotional distress, cognitive function, and quality of life in patients with cancer treated with chemotherapy.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-75

21 January 2018

Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-75

21 January 2018

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-75

21 January 2018

A note on quantifying follow-up in studies of failure time

1 reference

https://pubmed.ncbi.nlm.nih.gov/21324184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Docetaxel administered on a weekly basis for metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21324184

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-11-75

1 reference

Europe PubMed Central

29 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33821528&oldid=1785321442"